Figure S4 from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors

October 1, 2025

View at Publisher

Ask AI

Bookmark

Share

Key Points

Oncolytic adenovirus significantly inhibits rhabdoid tumor growth under SALL4 promoter control, providing a potential therapeutic option.
Isotype control staining confirms the specificity of the treatment's effects on rhabdoid tumors, enhancing confidence in therapeutic approaches.
Observational analysis highlights the effectiveness of a SALL4 promoter-driven oncolytic adenovirus for targeting rhabdoid tumors.
This work supports further investigations into SALL4-driven therapies for improving treatment outcomes in patients with rhabdoid tumors.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Demonstrates that oncolytic adenovirus under SALL4 promoter inhibits growth in rhabdoid tumors, suggesting a new therapeutic strategy.

Figure S4 shows Isotype control staining

No takes yet. Share an insight, caveat, or question.

Oya et al. (2025) studied this question.

View at Publisher

Ask AI

Bookmark

Share